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Abstract
In this review, we discuss recent work by the ENIGMA Consortium (http://enigma.ini.usc.edu) – a 
global alliance of over 500 scientists spread across 200 institutions in 35 countries collectively 
analyzing brain imaging, clinical, and genetic data. Initially formed to detect genetic influences on 
brain measures, ENIGMA has grown to over 30 working groups studying 12 major brain diseases 
by pooling and comparing brain data. In some of the largest neuroimaging studies to date – of 
schizophrenia and major depression – ENIGMA has found replicable disease effects on the brain 
that are consistent worldwide, as well as factors that modulate disease effects. In partnership with 
other consortia including ADNI, CHARGE, IMAGEN and others1, ENIGMA's genomic screens – 
now numbering over 30,000 MRI scans – have revealed at least 8 genetic loci that affect brain 
volumes. Downstream of gene findings, ENIGMA has revealed how these individual variants – 
and genetic variants in general – may affect both the brain and risk for a range of diseases. The 
ENIGMA consortium is discovering factors that consistently affect brain structure and function 
that will serve as future predictors linking individual brain scans and genomic data. It is generating 
vast pools of normative data on brain measures – from tens of thousands of people – that may help 
detect deviations from normal development or aging in specific groups of subjects. We discuss 
challenges and opportunities in applying these predictors to individual subjects and new cohorts, 
as well as lessons we have learned in ENIGMA's efforts so far.
Introduction
Here we provide an update on the progress of the ENIGMA consortium, a global alliance of 
over 500 scientists from over 200 institutions in 35 countries to study brain imaging data 
worldwide, discovering factors that modulate brain structure, integrity, connectivity, and 
patterns of brain differences in major brain diseases. Founded in 2009, ENIGMA's initial 
aims were to perform genome-wide analyses to identify common variants in the genome that 
are reliably associated with normal variability in brain structure. Since the initial effort 
discovered consistent effects worldwide of genetic variants that explained less than 1% of 
the variance in brain measures (Stein et al., 2015; Hibar and the CHARGE and ENIGMA2 
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Consortia, submitted for publication; Hibar et al., 2015a,b, in press), over 500 scientists have 
joined ENIGMA. ENIGMA is now (as of October 2015) a worldwide consortium, organized 
into over 30 working groups, studying major brain diseases (detailed at http://
enigma.ini.usc.edu). The work in ENIGMA is divided into projects on (1) genetics, 
screening genomic data for predictors of individual variations in brain structure, function, 
and connectivity; (2) disease, screening brain measures to identify patterns of differences in 
the major brain diseases and factors that affect them; and (3) methods development. New 
“Big Data” methods are being developed and implemented around the world to perform 
genetic analysis of high-dimensional features that arise in neuroimaging — such as brain 
networks or “connectomes” (Sporns et al., 2005), 3D or 4D maps of brain changes over 
time, and more complex imaging data from functional MRI and EEG/MEG.
For this issue of NeuroImage we review the work ENIGMA has done, and how it relates to 
making individual predictions to support the emerging discipline of precision medicine — 
where personalized medical decisions are made considering an individual's genetic make-up, 
other risk factors, and the large body of scientific knowledge detailing genotype-phenotype 
relationships. ENIGMA's genetic and disease-related studies are discovering new factors that 
affect the brain throughout life, how the diseased brain differs from the healthy brain, and 
how patterns of brain measures differ from one disease to another. The potential to use 
machine learning methods in this context is vast, and we point to future opportunities and 
challenges, and what we have learned already about how individual genetic variants and 
diseases affect the brain.
One major thrust of ENIGMA's work is genomics, so we first review studies that discovered 
individual loci in the genome that are linked to variations in brain structure (Stein et al., 
2012; Hibar and the CHARGE and ENIGMA2 Consortia, submitted for publication; Hibar 
et al., 2015a,b, in press). The effect of these common genetic variants tends to be small, but 
the aggregate effect of thousands of them accounts for a substantial proportion of the 
variance in brain measures (Toro et al., 2015; Ge et al., 2015; Chen et al., 2015). The 
relevant genes can be difficult to discover in individual cohorts, but they can be detected by 
meta-analyzing data across multiple sites. We discuss multivariate and machine learning 
methods needed to combine some of these predictors in more powerful models that can 
make valuable predictions about individuals, such as predicting deviations from normal 
lifetime aging, risk for mental illness, or recovery from trauma.
Reproducibility
There have been numerous recent surprises regarding the nature of gene effects on the brain, 
including surprisingly poor reproducibility of candidate gene effects on imaging measures 
and risk for mental illness, and the very large sample sizes needed to reliably detect any 
genetic associations at all. There have also been dramatic claims of poor reproducibility of 
findings in genetics, neuroimaging, and neuroscience studies in general (Button et al., 2013; 
Ioannidis, 2014; Ioannidis et al., 2014). Meta-analyses, such as those conducted by 
ENIGMA, have been proposed as a way to screen for false positive findings. If claims of 
“significance chasing” and “fishing” in neuroscience studies are true (Ioannidis, 2014), then 
predictive models based on them should fail more often than models based on meta-analyzed 
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studies of large numbers of independent cohorts, analyzed in a harmonized way (Ware and 
Munafò, 2015). ENIGMA is dedicated to replication, and a number of initiatives are 
underway to develop methods to replicate imaging genomics findings.
We discuss factors that affect reproducibility of models that predict specific gene effects on 
the brain, including technical factors of image acquisition and analysis. Low effect sizes for 
individual predictors make genetic effects hard to detect, so meta-analysis is valuable in 
demonstrating effects that no single cohort can detect on its own. Clearly, if we build a 
model to classify a person into a certain diagnostic group, based on a set of predictors, we 
also need to know how to decide if we have measured the predictors well enough, or if the 
context where the model was fitted is similar enough to the current situation for the 
prediction to make sense and be accurate. Apart from the choice of predictive model and 
predictors, there are many other reasons why imaging or genetic models of diagnosis or 
prognosis may generalize poorly or not at all, depending on the context. Factors that affect 
model prediction will include age and environment, and the demographic history of the 
populations sampled; these may affect whether or not a predictor is relevant to a new cohort 
or an individual. In the ENIGMA studies below, we point to examples in which predictors in 
the genome and image would be valuable in making individual predictions about brain 
volume or about a person's diagnosis, but only in certain contexts, such as in certain parts of 
the lifespan, or only after considering certain confounds or variables that are known to drive 
brain differences (duration of medication and duration of illness are often confounded, and 
modeling each effect independently may produce paradoxical conclusions, e.g., that 
medication is bad for the brain). Individual predictive models are likely to become 
increasingly nuanced, as we find out more about how predictors interact and contexts where 
different models work best.
In the course of ENIGMA's efforts, a vast quantity of normative data has been gathered and 
analyzed from different countries and continents of the world, allowing us to make some 
inferences about the normal trajectory of brain development and aging (ENIGMA-Lifespan; 
Dima et al., 2015). We discuss the challenges and opportunities in using models based on 
these data to make assertions about individual and group deviations from normal, or to 
generate cohort, or national norms, if they exist and if their value outweighs the costs of 
generating them.
We also discuss several concepts that have increased the power of ENIGMA to find factors 
with very small effects on the brain, including how we assess their generality and 
extensibility to new cohorts.
ENIGMA's Genetic Studies
By December 2009, many researchers worldwide had collected genome-wide genotyping 
data from cohorts of subjects for whom brain imaging information such as anatomical MRI 
was available.
It had long been presumed that genetic and environmental factors, and the complex 
interactions among them, play a role in shaping brain structure. Decades of work in 
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behavioral and medical genetics had convincingly shown that many of the major brain 
diseases – from Alzheimer's and Parkinson's disease to psychiatric illnesses such as 
schizophrenia and major depression – had a strong additive genetic component. Similar 
genetic risks exist for neurodevelopmental disorders such as autism. Even so, studies of 
identical twins who share the same genome show that genetic factors do not fully account 
for disease risk, and discordant twin pairs provide valuable information about the impact of 
environmental and epigenetic factors on disease (Munn et al., 2007). Furthermore, many 
common disorders are likely to reflect a constellation of modest gene differences acting in 
concert, which smaller individual studies are unlikely to find. Instead, larger studies that 
capture heterogeneity have begun to unravel the influence of multiple ‘low level’ minor but 
important gene differences on disease expression (Lopez et al., 2015).
As high-throughput genotyping methods became available, genome-wide association studies 
(GWASs) began to reveal specific sources of risk in the genome for several major brain 
diseases (Fig. 1). To fully appreciate this kind of study, we need to understand that much of 
the genome is invariant between humans (Rosenberg et al., 2002). Many kinds of individual 
genetic variations – common or rare – can occur, including polymorphisms, insertions and 
deletions of genetic material, loss or retention of homozygosity (LOH/ROH), or copy 
number variations (CNVs) — where the number of copies of pieces of genomic material 
differs from the normal two alleles in some individuals but not others. Polymorphisms are a 
common marker of individual differences, where a single nucleotide polymorphism (SNP) is 
essentially a “single-letter” change in the genome: a change in a single base pair between 
individuals.
Some genomic changes interfere with the viability of the organism, leading to very low 
frequencies in the population. Others remain and some have a moderate or severe impact on 
a person's health, or their risk for disease. For example, a common variant (present in 1 in 
100 in the general population) in the HFE gene impairs a person's ability to metabolize iron. 
Excessive iron levels can then accumulate in bodily organs, which can cause liver and 
kidney failure. Multiple deletions in the 22q region of the genome provide another example. 
Individuals with these deletions have a characteristic neurodevelopmental profile associated 
with mild to severe abnormalities in the face, brain, and heart, and are at heightened risk for 
schizophrenia and autism. 22q deletions occur frequently de novo, so they do not really 
remain in the population; rather 22q is a vulnerable spot in the genome for mutation. Even 
so, 22q deletion syndrome – and other neurogenetic disorders such as Fragile X, Williams 
syndrome, and Turner syndrome – have often been studied to help identify potential 
mechanisms that may contribute to more prevalent psychiatric conditions. ENIGMA's 22q 
working group has been set up to understand brain differences associated with deletions at 
this locus, and how they relate to those found using the same analysis protocols in 
ENIGMA-Schizophrenia and ENIGMA-Autism.
Genetic risk for many major psychiatric illnesses is thought to be mediated in part by 
common genetic variants that have persisted in human populations for thousands of years. In 
many cases, the adverse effects of disease risk genes – such as the Alzheimer's risk gene, 
APOE – are not apparent until later in life (Hibar and the CHARGE and ENIGMA2 
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Consortia, submitted for publication; Hibar et al., 2015a,b, in press). Because of this, the 
variants tend to be preserved in the gene pool and continue to drive disease risk worldwide.
Geneticists continue to debate the relative contribution of common versus rare genetic 
variants to risk for various diseases, but a recent large-scale screen of schizophrenia patient 
cohorts worldwide implicated over 100 genetic loci in risk for the disease (Ripke et al., 
2014; Fig. 1). This highly successful study pointed to several genes in the dopamine 
neurotransmission pathway that had long been implicated in schizophrenia and its treatment 
— for example, a functional polymorphism in the DRD2 promoter region, which modulates 
levels of gene expression, and affects antipsychotic drug efficacy (Zhang and Malhotra, 
2013). This same genomic screen pointed to other unexpected genetic variants in immune 
system pathways that offer tantalizing new leads about disease mechanisms, and the role of 
modifiable factors in eventually treating or averting the illness. Similar efforts in bipolar 
illness, major depression, and ADHD uncovered genes driving risk for these disorders that 
overlapped to some extent with those for schizophrenia and with each other (Cross Disorders 
Working Group of the Psychiatric Genomics Consortium, 2013). Members of the ENIGMA 
Consortium have recently demonstrated the usefulness of polygenic risk scores for 
schizophrenia (based on the 108 loci shown in Fig. 1A) in revealing an association between 
early cannabis use and brain maturation during adolescence — replicated in three samples 
(French et al., 2015).
Many successful genomic screens involve over 100,000 individuals. For example, the most 
recent GWAS of height, educational attainment, and body mass index (BMI) identified 56 
novel BMI-associated loci in a sample of up to 339,224 individuals (Wood et al., 2014; 
Locke et al., 2015). Similarly, the Psychiatric Genomics Consortium's discovery of genetic 
loci implicated in schizophrenia risk took a ‘quantum leap’ once the sample sizes exceeded 
75,000 (Ripke et al., 2014), after less successful searches in smaller samples. Several factors 
may contribute towards this need for large sample sizes in genome-wide association. First, 
there are biological variation and ascertainment differences among cohorts. A person 
diagnosed with a specific illness may have other co-morbid illnesses, and diagnostic criteria 
may vary somewhat worldwide in terms of who is included in the groups of patients and 
controls.
However, the main reason GWAS needs large samples is power: a genome-wide association 
analysis comprises approximately a million independent tests, so a threshold of p < 5 × 10–8 
is employed to minimize false positives. Early GWAS estimated their required sample sizes 
based on published effect sizes of candidate genes that have since been shown to be greatly 
overestimated. Although the genetic architecture of each trait is unique, for most complex 
traits the effect sizes of individual SNPs are typically less than half a percent (Franke et al., 
in press). Thus, it follows from power analyses that GWAS and GWAS meta-analyses 
typically require data from tens of thousands of individuals.
In the imaging field, initial studies also attempted genome-wide screens of brain imaging 
measures, such as brain size (Paus et al., 2012), the volume of the temporal lobes on MRI 
(Stein et al., 2010a,b), in cohorts of around 800 subjects (see Medland et al., 2014, for a 
review). This type of analysis became feasible as large cohort studies, such as the 
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Alzheimer's Disease Neuroimaging Initiative (Jack et al., 2015), started to put their images 
and genomic data online. In line with accepted practice in genetics, it is customary to require 
replication of such genetic effects in independent cohorts.
While some effects appeared to replicate, most did not as the studies were underpowered, 
and it was unclear whether cohort factors, biological differences, or technical factors were to 
blame.
Endophenotype Theory and Power
As the field of imaging genetics grew, some researchers hoped that imaging might offer a 
more efficient approach to discover genes involved in mental illness. The reason for this 
optimism was based on the observation that many brain measures are consistently reported 
as affected in psychiatric cohort studies (see later, under ENIGMA Disease Studies), so they 
could maybe serve as quantitative traits, or markers, correlated with the illness.
There was also some hope that the biological signals in images – measures of 
neurotransmitters, receptors or metabolite levels, blood flow, the volume of specialized brain 
areas such as the hippocampus, or its chemical content – might be influenced by genetic 
variants because of their proximity to primary gene action. Likewise, it was argued that 
brain-derived measures may have a simpler genetic architecture – perhaps with fewer 
individual genes or pathways influencing them – compared to the multitude of factors 
driving a person's overall risk for developing a disease (Saykin et al., 2015). Brain measures 
may also offer a more precise or reproducible diagnostic scale. Potkin et al. (2009) noted 
that GWAS can be more efficient when researchers analyze continuous measures (such as 
brain volumes) rather than binary traits, such as diagnosis, which may also disguise 
complexities such as co-morbidity, etc.
This endophenotype theory2 led to confidence that genome-wide screening of brain 
measures would yield “hits” – genetic loci consistently associated with brain measures – 
relatively efficiently and, some believed, in much smaller samples. Several countervailing 
arguments should also be considered. The genetics of brain traits may reveal common 
pathways involved in a number of mental illnesses, but one loses some specificity when 
moving from a psychiatric disorder to brain measures — different disorders may have very 
similar brain abnormalities. For this reason, ENIGMA's Disease Working groups have 
analyzed tens of thousands of brain scans to see which measures best distinguish patients 
from controls, across a range of 12 diseases, with a view to understanding similarities and 
differences. Collecting brain imaging data is more expensive than diagnostic testing. Also, 
genes that affect brain measures may be of less interest to a patient or physician unless they 
are also connected to disease risk or prognosis. In ENIGMA, however, the costs of collecting 
the imaging data had already been incurred, making the feasibility of a large-scale analysis 
the main consideration. Others voiced a muted optimism: Munafò and Flint (2014) noted 
2The term “endophenotype” was coined by John and Lewis (1966); in psychiatric genetics, it is used to denote a biomarker that fulfills 
several criteria (Gottesman and Gould, 2003; Glahn et al., 2014), including heritability, reproducible measurement, segregation with 
illness in families and in the general population, and state-independence — it must remain stable when a patient's illness is active or in 
remission. Others used the term “intermediate phenotype” for the brain measures studied in imaging genetics, as the endophenotype 
refers to the characteristics that are shared by both patients and their unaffected first-degree family members.
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that effect sizes for gene effects on neuroimaging data were not likely to be any greater than 
for any other trait, but the value in studying them came from the ability of brain measures to 
help understand mechanisms that might underlie associations between genes and more 
conventional traits (see also Flint et al., 2014). Yet, the potential to find genetic factors that 
jointly influence risk for mental illness and a neuroimaging trait could dramatically improve 
statistical power and provide an important link between the genome and the behavioral 
symptoms used to diagnose psychiatric and neurological illnesses (Glahn et al., 2014).
In ENIGMA's first paper in Nature Genetics, Stein and 158 authors (2012), including 4 
existing consortia (SYS, EPIGEN, ADNI, and IMAGEN3), meta-analyzed GWAS data from 
cohorts worldwide and found genetic loci consistently associated with the size of the human 
hippocampus and total intracranial volume. Notably, in a partnership with another 
consortium, CHARGE (Bis et al., 2012), the top “hits” – the genetic variants with greatest 
effect sizes – were anonymously exchanged and found to be the same, supporting the 
replicability of the findings in completely independently designed efforts.
In a follow-up study in a larger sample (N = 21,151 individuals; Hibar and the CHARGE 
and ENIGMA2 Consortia, submitted for publication; called “ENIGMA2”), eight genetic 
loci were discovered that were reliably associated with the size (volume) of several 
subcortical structures, including the putamen, caudate, and pallidum. With the increased 
sample size, earlier findings regarding the hippocampus and intracranial volume were 
replicated and reinforced; new genetic loci were also discovered. Several of the SNPs 
implicated lie within or close to genes involved in cell migration, axon guidance, or 
apoptosis — all cellular processes likely to lead to observable differences in the size of 
cellular nuclei in the brain. Parallel work in mice by the Williams lab in Memphis began to 
study mouse homologs of these variants (Ashbrook et al., 2014); recent data suggest that 
variation of the top putamen gene, KTN1, can predict putamen volume and cell counts in 
outbred mice (R. Williams, pers. commun.).
Several lessons were learned from the first two ENIGMA genetic studies, in addition to a 
third pair of papers currently in submission, involving an even larger sample (N > 31,000; 
Hibar and the CHARGE and ENIGMA2 Consortia, submitted for publication; Hibar et al., 
2015a,b, in press; Adams and the CHARGE and ENIGMA2 Consortia, submitted for 
publication). First, through meta-analyses, it was possible to detect factors (here, SNPs) that 
accounted for less than 1% of the variance in brain measures. This was despite the fact that 
the participating studies were designed with different goals in mind, and many used scanners 
of different field strengths, processed by researchers who had not all met, and communicated 
through email and teleconference calls.
Much of the consistency in brain measures capitalized on the ongoing refinement of 
standardized protocols for analyzing images and genomes; in turn, those protocols relied on 
decades of work by developers of widely used and extensively tested analysis packages such 
as FreeSurfer (Dale and Sereno, 1993; Fischl, 2012), and FSL (Jenkinson et al., 2012). The 
3Abbreviations: SYS, Saguenay Youth Study, http://www.saguenay-youth-study.org; EPIGEN, The Epilepsy Genetics (EPIGEN) 
Consortium (Cavalleri et al., 2007); ADNI, Alzheimer's Disease Neuroimaging Initiative (http://www.adni-info.org); IMAGEN, 
IMAging GENetics Consortium (http://www.imagen-europe.com).
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supplement of the first ENIGMA paper (Stein et al., 2012) contained 104 pages of ancillary 
tests supporting the validity and reliability of the data, including tests comparing different 
imaging software for brain volume quantification.
On the genomic side, the ability to compare genomic data in a common reference frame 
depended on the availability of the HapMap3 (The International HapMap3 Consortium, 
2010) and later the 1000 Genomes reference datasets (Genomes Project C et al., 2010). 
These reference panels are continually updated and refined, and allow genotyping data 
collected with one kind of genotyping array (“chip”) to be imputed to match data collected 
using others, and pooled in the same overall study.
A second issue is whether these findings could have been detected more efficiently using 
only some of the samples. In a sense, this is a “meta-question” — how might the study have 
been designed more efficiently after seeing the results?
As in any meta-analysis, the weight assigned to each cohort in the final statistics can be 
made to depend on its total sample size, or on the standard error of the regression 
coefficients (which is in fact what ENIGMA does). As such, it is not vital for every cohort to 
reject the null hypothesis on its own. In fact, any cohort study, however small, can partner 
with other sites to contribute to the discovery of effects that it cannot detect alone. In 
ENIGMA1 (Stein et al., 2012), only 5 of the 21 cohort studies were able to detect the effect 
of the SNPs on the brain in their cohort alone, at the nominal significance level of p = 0.05. 
By the time of ENIGMA2, 20 of the 38 Caucasian European (CEU) cohort studies could 
detect the effects of the top SNP. Even so, the aggregate support of the discovery and 
replication samples was crucial to making sure the effects were credible and unlikely to be 
false positives.
Relevance to Disease Risk
The quest to identify genetic variants associated with brain measures is partly motivated by 
finding variants that affect our individual risk for disease. Any modulators of health 
outcomes in populations may have a vast impact on society, even if they are not the main 
factors explaining risk for any one individual. As well as affecting risk for disease, genetic 
differences may also affect symptom severity, treatment response, and prognosis.
As such, several clinical trials for Alzheimer's disease drugs already stratify their cohorts by 
APOE genotype — a major risk gene for AD that may have a bearing on treatment response 
as well as disease risk (see Riedel et al., submitted for publication, for a review of APOE 
effects, which are remarkably complex). At the time of writing, several manuscripts are 
under review addressing the overlap between ENIGMA's genomic findings and accepted or 
emerging markers of disease risk (Hibar and the CHARGE and ENIGMA2 Consortia, 
submitted for publication; Hibar et al., 2015a,b, in press; Adams and the CHARGE and 
ENIGMA2 Consortia, submitted for publication; Franke et al., in press). Here we simply 
review their overall design. Some initial reports have appeared in abstract form, relating 
brain-related SNPs to risk for Parkinson's disease (Hibar and the CHARGE and ENIGMA2 
Consortia, submitted for publication; Hibar et al., 2015a,b, in press), obsessive compulsive 
disorder (Hibar and the CHARGE and ENIGMA2 Consortia, submitted for publication; 
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Hibar et al., 2015a,b, in press), schizophrenia (Stein et al., 2015; Franke et al., in press), and 
multiple sclerosis (Rinker et al., submitted for publication). An initial negative report has 
appeared for epilepsy (Whelan et al., 2015). Even so, given the low fraction of heritability 
explained by the SNPs discovered, the studies so far are widely accepted as underpowered.
One method to assess an individual's relative risk for disease, based on genome-wide 
genotyping data, involves computing a polygenic risk score (PRS) for each individual. In 
Alzheimer's disease, for example, carrying one copy of the APOE4 genotype boosts lifetime 
risk for AD by a factor of 3, and carrying two copies may boost risk by 15 times. These odds 
ratios are not constant across human populations and even vary by ethnicity, or 
circumstances, so some caution is needed when extrapolating them to new data; but as AD 
GWAS data accumulate, over 20 common genetic variants have been found to affect AD risk 
— 3 of them, in the genes CLU, PICALM, and CR1, appear to be associated with a 
difference in disease risk of over 10% per allele. If an individual's genotype is known for 
these loci, it is possible to create a polygenic risk score in a number of different ways, 
depending on whether the goal is to predict diagnosis, outcome, or brain measures. The 
simplest approach is to count risk loci, although that clearly ignores the vastly different odds 
ratios from each locus. It is more common to weight the loci based on their odds ratio for 
disease, or by their regression coefficients. APOE4, for example, is just a single genotype 
that might contribute to calculation of a polygenic risk score together with other risk loci. As 
shown by the PGC analyses, the predictive accuracy of PRS scores increases as the number 
of variants included increases. Calculation of these scores does not need to be restricted to 
genome-wide significant loci.
Recent efforts to predict disease status based on polygenic risk scores have had varied 
success, but the reasons are quite well understood. First, for the most prevalent neurological 
or psychiatric diseases, we do not yet have a set of common variants that account for more 
than a small fraction of disease risk (except for APOE4, where a single copy may triple a 
person's risk for AD, other factors being equal). In AD, there are rare mutations in genes 
related to AD pathology – such as presenilin and APP – that invariably produce early-onset 
AD. Carriers of these genetic variants are the targets of major neuroimaging initiatives 
(Benzinger et al., 2013). A very important aspect of this – relevant to the field of 
personalized medicine – is that the person's genotype in conjunction with amyloid imaging 
can accurately predict the age of onset for the disease and the symptoms (Benzinger et al., 
2013).
Another cause for optimism is the efforts of the Psychiatric Genomics Consortium (PGC). 
When the PGC Schizophrenia Working Group increased their sample size to 36,989 cases 
and 113,075 controls, they discovered over 100 loci associated with risk for schizophrenia, 
suggesting that other GWAS may experience similar boosts, depending on where they are in 
the arc of discovery. The rate of success of these efforts, and yield on the efforts invested, 
also depends on the polygenicity of each disease, and the distribution of risk loci across the 
genome. Holland et al. (submitted for publication) used recent data from the ENIGMA study 
and the PGC to estimate what sample sizes are needed for a GWAS to discover enough 
SNPs to account for, say 50% or 80% of the chip-based heritability, i.e., the amount of the 
population variance predictable from genotyped SNPs. They argued that some traits are 
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more polygenic than others, and that, relative to some brain measures, GWAS studies of 
schizophrenia and major depressive disorder may require much larger sample sizes to 
discover enough SNPs to account for high levels of the chip-based heritability. If that is true, 
then imaging genetics may be well on the way to a significantly higher rate of discovery, and 
a more complete understanding of common variants driving individual differences in brain 
measures.
How much individual variance is explainable by GWAS and common genetic variants?
In recent years, a number of powerful methods emerged to estimate what fraction of the 
population variance in a trait could be predicted, in principle, from all the SNPs on the 
genotyping chip, even if the exact genes and SNPs were not yet known.4 Predictions can be 
made from the full set of association statistics: models (linear or Gaussian) are first fitted to 
the observed effect sizes of all the SNPs, even if most SNP effects fail to reach the accepted 
standard for genome-wide significance. In much the same way as FDR (the false discovery 
rate method) is used in imaging to confirm evidence for a distributed signal — spread out 
across the brain, the overall effect of genome-wide SNPs on a trait can be estimated without 
having to pinpoint which exact regions — of the image or the genome — contribute 
unequivocally to the effect.
Hibar et al. (2015) used genome-wide summary statistics to estimate heritability (So et al., 
2011) and found that common variants across the genome explained around 19% of the 
variance in hippocampal volume, which is comparable to SNP-based estimates of 
heritability for many psychiatric disorders and other biological traits. More recently, B.K. 
Bulik-Sullivan et al., 2015 introduced a similar method based on linkage disequilibrium5 
(LD) scores that is also able to recover heritability from summary statistics. The LD score 
method assigns an LD score to each SNP — the sum of its squared correlations (r2) with all 
other SNPs in a 1 centimorgan window. One then regresses the chi-squared statistics from a 
GWAS against the LD score for each SNP. The slope of the resulting regression line depends 
on the sample size and the SNP-heritability — the proportion of trait variance accounted for 
by all the genotyped SNPs (see B. Bulik-Sullivan et al. (2015), B.K. Bulik-Sullivan et al., 
2015, for derivations).
A related method, GCTA (genome-wide complex trait analysis; Yang et al., 2011) suggested 
that a still higher proportion of population variance in brain volumetric measures may be 
accounted for based on all genotyped SNPs, even in cases where we do not know which 
SNPs help as predictors of the trait. Members of the ENIGMA Consortium have applied this 
method to estimate SNP-based heritability for structural (Toro et al., 2015) and functional 
(Dickie et al., 2014) brain measures. A working group in ENIGMA, ENIGMA-GCTA, is 
now comparing the GCTA and LD score methods to better estimate how much brain 
4Obviously the SNPs are “known” in the sense that they are on the genotyping chip. The issue is that we do not know exactly which 
specific sets of SNPs or genes are truly contributing to a trait.
5Linkage disequilibrium is the presence of statistical associations between alleles (genomic variants) at different loci in the genome, 
which arise because nearby regions on the genome tend to be inherited together. Maps of the level of LD between adjacent SNPs on 
the genome have been compiled for multiple ethnic groups. In imaging, LD leads to peaks of association with brain measures, and 
these LD maps can be used analytically to estimate SNP-based measures of heritability or genetic correlations from GWAS summary 
statistics.
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variation is explainable by genotyped SNPs, at least for the brain measures that are most 
readily computed from MRI. SNP-based heritability estimates of cortical surface area for 
different cortical subdivisions calculated by GCTA were recently published (Chen et al., 
2015). These cortical subdivisions were defined by a genetically based cortical parcellation 
scheme (Chen et al., 2012).
The reason ENIGMA and other GWAS researchers are interested in measuring heritability – 
and ideally the fraction of heritability explained by common genetic variants – is that it 
should be possible to prioritize brain measures for deeper genetic analysis based on their 
heritability, reliability, polygenicity, and relevance to disease. Such rankings or “Bayesian 
priors” would help in prioritizing research, making studies more efficient and better powered 
(Schork et al., 2013; Becker et al., submitted for publication; Holland et al., submitted for 
publication; Wang et al., submitted for publication). Even so, there is no evidence that 
phenotypes with higher heritability show stronger associations with SNPs. One such 
example is white matter hyperintensities — a brain measure with high heritability, for which 
specific genomic risk factors have been hard to find. The main benefit of focusing on highly 
heritable phenotypes comes from the fact that measurement error is typically lower, and 
prioritizing brain measures is important as there are so many ways to quantify brain structure 
and function.
A recurring caveat in this work is that the SNP effects are not expected to be constant in all 
cohorts. They may depend on a person's age, environment, or other circumstances. We now 
know from ENIGMA2 that the top 8 loci associated with the volumes of subcortical 
structures were detectable consistently worldwide, even though each one accounts for < 1% 
of the variance. A later screen for age × SNP effects suggested that some genes have a 
greater effect on brain measures later in life (Hibar and the CHARGE and ENIGMA2 
Consortia, submitted for publication; Hibar et al., 2015a,b, in press), perhaps because they 
interact adversely with other biological processes or environmental stressors. In other words, 
although ENIGMA primarily uses meta-analysis to assess evidence, we do not assume that 
the effect size is always the same. Heterogeneity of effects is also assessed – a SNP effect 
important late in life may not be replicated in younger samples. Conversely, since most 
psychiatric disorders occur at a young age, one may expect to find associations that link 
genetic vulnerability, brain structure and disease at a younger age, with effects that may 
diminish later. Moreover, for certain disorders such as addiction, the psychological, 
neurobiological and genetic factors most relevant at one age (e.g., impulsivity or sensation-
seeking in adolescents experimenting with drugs) may be quite different from the factors 
when dependent (e.g., compulsivity or habit-based behavior) or when recovering (e.g., stress 
regulation or cognitive control). Even so, ENIGMA's genomic screens so far are only well-
powered to detect SNP effects that are consistent — there may also be SNP effects, so far 
undetected, that depend on the demographics of the cohort assessed, or disease status, or 
other circumstantial factors.
This is a reminder that predictive models work best in cohorts similar to those where 
discoveries were made. Because of this concern, which to some extent affects all brain 
imaging studies — and all human studies — ENIGMA has diversified to over 33 countries. 
Recently, ENIGMA partnered with other consortia such as the Japanese consortium, 
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COCORO (Okada et al., in press); encouragingly, effects of psychiatric illness on brain 
structural measures were replicated in Western and Eastern populations, not just in the 
structures affected the most, but in their rank order, showing congruence between 
independent studies (van Erp et al., 2015; Okada et al., in press).
ENIGMA's Disease Studies
After the initial success of the genetic analyses (Stein et al., 2015; Hibar and the CHARGE 
and ENIGMA2 Consortia, submitted for publication; Hibar et al., 2015a,b, in press), 
ENIGMA investigators had analyzed brain MRI data from well over 30,000 individuals — 
around a third of the data came from patients with a range of psychiatric conditions. In the 
primary GWAS studies, analyses were run with and without patients, and excluding patients 
did not affect the main findings; of course the possibility remains that some SNP effects may 
be easier to detect in some patient cohorts, but ENIGMA's overall results were not driven by 
the presence of patients.
In 2012, ENIGMA formed working groups on schizophrenia (van Erp et al., 2015), bipolar 
disorder (Hibar and the CHARGE and ENIGMA2 Consortia, submitted for publication; 
Hibar et al., 2015a,b, in press), major depression (Schmaal et al., 2015), and ADHD 
(Hoogman et al., 2015); groups meta-analyzing data on 8 additional disorders have been 
formed since, with current sample sizes detailed in Table 1; a map of participating sites is 
shown in Fig. 2. In the summer of 2015, additional working groups were formed on anorexia 
nervosa, recovery after stroke, and Parkinson's disease — the current “roadmap” showing 
relationships between ENIGMA's working groups is shown in Fig. 3 (also see http://
enigma.ini.usc.edu for the latest status). The diseases surveyed include many where 
controversy exists on the nature and scope of disease effects on the brain. Given this 
controversy, the main benefit of meta-analysis is to discover which effects are strongest or 
most reliably found, and which depend on known or unknown factors of the cohorts 
assessed.
The initial goal of ENIGMA's Disease working groups has been to meta-analyze effects of 
these disorders on the subcortical brain measures studied in the GWAS study. As scans had 
already been analyzed with a harmonized protocol, and subtle genomic effects had been 
discovered, there was some interest in ranking brain measures in terms of disease effects 
(i.e., differences between patients and controls).
A secondary goal was to find factors that might moderate how these diseases impact the 
brain, such as a person's age, the duration or severity of illness, comorbidities, or treatment-
related effects, such as which medications the patients had been treated with, and for how 
long. Clearly, treatment effects on the disease or the brain depend on many factors. 
ENIGMA's multiple cohorts, in some cases, offered the opportunity to gauge their generality 
or consistency. At the same time, many groups joined ENIGMA and provided only brain 
measures as their initial case–control analyses did not require genome-wide genotyping data 
on their cohorts. As such, truly vast samples began to be analyzed (N = 8,927, in the 
published ENIGMA-Depression study; N = 10,194 in the ENIGMA-Lifespan study; see 
Table 1).
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At the time of writing, ENIGMA's first studies of schizophrenia and major depression have 
been published; results are compared in Fig. 4. Some caveats are needed in showing these 
data side by side: the schizophrenia and major depression patients were not ascertained at 
the same sites, so site or geographic effects may be present.
Among the subcortical structures so far assessed, the hippocampus shows the greatest 
differences in each disorder in terms of statistical effect sizes — but in major depression, it 
is the only structure showing differences, of those assessed so far (Schmaal et al., 2015). 
Many other structures show volume deficits or even hypertrophy in schizophrenia; basal 
ganglia enlargement has been widely noted in prior studies of patients taking second-
generation antipsychotics. In people with schizophrenia, abnormal ventricular enlargement 
has long been reported (as far back as Johnstone et al., 1976), but the natural variations in 
ventricular size make the effect size smaller for this structure, even though the absolute 
volume difference, on average, is greater than for other structures assessed. In major 
depression, the hippocampal volume difference was greater in patients who experienced 
more depressive episodes, and in those diagnosed before the age of 21 years, which were at 
least partly independent effects. This is in line with many prior reports of greater brain 
differences in those with an earlier onset of the disease. Studies of cortical measures are now 
underway across all ENIGMA disease working groups; many cortical regions are commonly 
implicated in psychiatric illness, so these analyses may offer a more complete picture 
relating brain structural differences to clinical measures, medications, and outcomes. At the 
same time, diffusion imaging studies are also underway; initial reports reveal consistent 
deficits in fractional anisotropy – a measure of white matter microstructure – for major white 
matter tracts in schizophrenia (Bora et al., 2011; Holleran et al., 2014; Ellison-Wright et al., 
2014; Kelly et al., 2015); an interesting question is whether antipsychotic medications affect 
white matter (Ahmed et al., 2015) and brain connectivity (O'Donoghue et al., 2015) in a way 
that fits with their known effects on structural anatomy.
Extensions and Refinements
Because of the worldwide scope of the ENIGMA studies, only the brain measures that were 
most readily measured have so far been examined. Clearly, there are measures that may be 
more relevant to each disease or closer to the action of disease-causing genes, but if they are 
difficult to harmonize and measure in a standard way, the available sample sizes will lag 
behind those available for the simpler measures. Because of decades of work on shape 
analysis of anatomy, several of the ENIGMA disease groups have begun to analyze and 
meta-analyze subcortical shape (Gutman et al., 2015a,b,c), to map the profile of volumetric 
effects with more spatial precision. These efforts will also determine whether shape metrics 
offer additional predictive value over and above standard metrics, and in which situations.
The ENIGMA-Laterality group is studying global trends in the profile of left–right 
differences in brain structure, and whether they relate to handedness, sex, and disease status, 
in over 15,000 people (Guadalupe et al., 2015, submitted for publication). Reduced or 
abnormal brain asymmetry has been reported in many brain disorders (Okada et al., in 
press), but the scope and generality of these differences is not yet understood. Also, many 
important aspects of human brain function show lateralization in terms of the underlying 
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processing networks, but the biology of this specialization is poorly understood, as are 
factors that influence it. Whether brain asymmetry measures add value as diagnostic 
predictors, will be testable across ENIGMA.
ENIGMA-EEG is studying the influence of genetic variants on brain functional activity 
measured with scalp recorded electrical signals, in a combined dataset from 10,155 
individuals, ranging from 5 to 74 years of age. EEG metrics of brain function mature rapidly 
with age, and relate to aspects of cognition such as the brain's processing efficiency; they 
also show abnormalities across many neurodevelopmental and psychiatric disorders. 
Combining data from several large twin and family datasets, the ENIGMA-EEG working 
group is performing a genome-wide association analysis of brain oscillatory power – a 
highly heritable trait – before proceeding to in-depth analyses of lateralized activity, brain 
connectivity, and network properties.
Brain-Wide Genome-Wide Association Studies
Voxel-based mapping methods are complementary to approaches that measure the volumes 
of specific regions of the brain, and they allow comprehensive and unbiased searches for 
effects of disease or genetic variations across the brain. “Brain-wide” genome-wide 
searches, or “voxelwise GWAS” (Shen et al., 2010; Stein et al., 2010a,b) can involve over a 
trillion statistical tests. However, once we account for the covariance within the image and 
genomic data, the number of independent tests being conducted drops to less than 15,000 × 
1,000,000. Given the extremely low p-values of some genetic associations in ENIGMA (p ~ 
10–23 in Hibar and the CHARGE and ENIGMA2 Consortia, submitted for publication; 
Hibar et al., 2015a,b, in press), several effects can still survive a “double” Bonferroni 
correction for multiple testing across both the image and the genome (Medland et al., 2014).
As a result, several recent approaches have been developed to perform brain-wide genome-
wide association studies to identify “spatial” features associated with genetic variants, such 
as specific WM pathways and their components, patterns of cortical thickness, or even 
activation patterns, rather than “global” measures such as brain or subcortical structure 
volumes. These approaches may be broadly divided into (1) “brute force” methods, that use 
mass-univariate testing to test every SNP for associations at each voxel in the image, and (2) 
data reduction methods, that attempt to reduce the search space by reducing the number of 
features in the image, or the genome, or both (Vounou et al., 2010, 2012; Ge et al., 2012). 
Data reduction methods may include classical methods, such as canonical covariates 
analysis, or independent components analysis (Gupta et al., 2015; Calhoun et al., 2015), or 
modern variants such as sparse coding, compressive sensing, or “deep learning” for feature 
discovery (see Thompson et al. (2013) for a review of multivariate imaging genomics 
methods). Among the “brute force” methods, Jahanshad et al. (2015a,b) detail a practical 
method whereby several sites run a voxel-based morphometric analysis independently, using 
a GWAS or other covariate-based analysis at each voxel, and later communicate their 
findings to a central site for meta-analysis (see Fig. 5). This approach was able to map out in 
the brain and meta-analyze the effects of the top SNP from the ENIGMA2 study, which 
screened the genome for variants associated with the size of subcortical structures (Hibar 
and the CHARGE and ENIGMA2 Consortia, submitted for publication; Hibar et al., 
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2015a,b, in press). To avoid re-computing everything when a new site joins, this “meta-
morphometry” approach allows cohorts to align their data to their own brain templates, 
which are later aligned to an overall mean template for meta-analysis. Such a distributed 
effort offers many advantages for imaging genomics, due to the vast number of predictors: as 
new cohorts join, each site's computational hardware can be leveraged by all the others. 
Such an approach allows cooperative computation on data without requiring all the data to 
be shared or ever transferred. This is an interesting area of cooperative machine learning that 
can also increase “buy-in” — opening up participation to countries with stricter data transfer 
laws.
As part of ENIGMA3, a genome-wide screen of the cortex, one subproject will adopt 
“genetic clustering” methods to identify coherent patterns of gene effects in the brain (Chen 
et al., 2013, 2015). Based on the notion of genetic correlation, brain regions or sets of voxels 
can be grouped into clusters with similar genetic determination. The standard decomposition 
of the brain into regions may be adapted to include genetic clusters, or new regions where 
genome-wide association may be more efficient (Chiang et al., 2012). This approach has 
already been applied to create genetic partitions of the cortex; initial work in ENIGMA will 
overlay pre-made partitions on the cortical data from each site. Genetic correlations can now 
be computed rapidly from GWAS summary statistics (B. Bulik-Sullivan et al., 2015; B.K. 
Bulik-Sullivan et al., 2015) making it feasible to compute and perform clustering on 
matrices of “genetic connectivity” whose entries are genetic correlations. The ENIGMA-
GCTA Working Group is currently studying these methods, in multisite data.
Many disorders affect the brain's white matter and connectivity. Using diffusion tensor 
imaging (DTI), ENIGMA's disease working groups have begun to compile evidence across 
cohorts for differences in a range of DTI measures, which reflect white matter integrity and 
microstructure (Kelly et al., 2015). Several years of work went into harmonizing ENIGMA's 
DTI analysis protocols, to study which metrics are consistently heritable and reproducible 
across multiple twin and family cohorts worldwide (Jahanshad et al., 2013a,b; Kochunov 
2014; Kochunov et al., 2015). These DTI protocols have been carried forward into ongoing 
GWAS and disease studies, and initial genome-wide screens of the structural connectome 
(Jahanshad et al., 2013a,b; de Reus et al., 2015). On the genetic side, ENIGMA working 
groups have also formed to assess other kinds of genetic variation, including copy number 
variants (CNVs), where abnormalities have been reported in autism, schizophrenia, and 
learning disabilities. The ENIGMA CNV helpdesk is now supervising supervising an initial 
analysis of CNV data in 13,057 people from 24 cohorts worldwide, after developing 
harmonized protocols for CNV “calling” and quality control. Participating cohorts include 
groups from Japan, Mexican-Americans, and people of Western European, Nordic or 
Swedish ancestry. Initial efforts are evaluating known “psychiatric” CNVs as predictors of 
MRI and DTI phenotypes computed in other ENIGMA projects. Challenges include the 
pooling of data from genotyping chips with different coverage; some have sparse coverage 
of SNPs in regions with segmental duplications or complex CNVs.
In a complementary initiative, the ENIGMA-Epigenetics working group is studying 
epigenetic processes such as methylation, which is an index of biological aging and 
lifecourse ‘stress’ that may explain an important proportion of the gene-environment 
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contribution to expression of many common diseases such as stroke and dementia. The 
group is now performing epigenome-wide association studies (EWAS), across 14 cohorts 
from Asia, Australia, North America, and Western Europe, to test associations between 
DNA methylation and brain measures, initially focusing on total brain volume, subcortical 
volumes and cortical thickness and surface areas. The working group is analyzing 
methylation data from 9,000 people, of whom 5,000 have both methylation data and MRI. In 
addition, the ENIGMA-Epigenetics group is prioritizing the analysis of DNA methylation 
sites based on their effects on gene expression or association with stress- and anxiety-related 
phenotypes. There is some evidence of early life changes in stress response genes through 
methylation (Backhouse et al., 2015), just as early life events influence later life disease 
expression — notably stroke, white matter hyperintensities, and cognitive impairment. Of 
great interest are epigenetic changes throughout the life span, and with aging, which may 
predict mortality from all causes, as well as physical and cognitive performance. 
Associations are being tested first for brain phenotypes that are known to change the most 
across the lifespan, based on incoming information from ENIGMA's Lifespan study in over 
10,000 individuals (Dima et al., 2015).
Relevance to Individual Evaluation, and Longitudinal Assessment
ENIGMA was not designed to make predictions about individuals based on their scans and 
genomic data. As in most epidemiological studies, the power lies in aggregating so much 
individual data that subtle effects on the brain can be detected, including findings that each 
cohort's data were insufficient to detect. In other words, its primary goal has been to relate 
brain measures to disease and treatment effects, and to variants in the genome. With the 
aggregated data, it has been possible to determine how reproducible these patterns are 
worldwide. Also, for the study of treatment effects, ENIGMA does not have the ideal 
design. Ideally, one would prefer to have pre–post treatment longitudinal designs instead of 
the cross-sectional comparisons in ENIGMA, where medication status is often confounded 
by age, disease duration, comorbidity and disease severity.
Even if a large data sample is needed to discover a factor that influences the brain, it does 
not mean that it is irrelevant to individuals; APOE is one such example, discovered in 1993 
by linkage analysis in pedigrees. More recently, a rare variant in the TREM2 gene (Jonsson 
et al., 2013; Rajagopalan et al., 2013) was found to affect Alzheimer's disease risk and 
accelerate brain tissue loss as we age — perhaps doubling loss rates in old age and 
increasing AD risk by a factor of 2–4. This gene variant is undoubtedly important for those 
who carry it: it is found in a little under 1% of controls and a little over 1% of AD patients.
How Does it Help to Predict Risk for Decline?
In current clinical practice, it is not recommended to notify a research participant of their 
APOE status, and most ethics boards clearly define the circumstances in which incidental 
findings or health-relevant information is communicated back to a research participant. In 
the case of APOE, participants are not typically informed of their genetic status, as there are 
no effective treatments for late–onset Alzheimer's disease. Still, discovering predictors of 
more rapid decline is useful for the pharmaceutical industry for understanding the behavior 
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of participants in clinical trials, and can greatly improve drug trial design, reducing costs. 
Enrichment approaches use some characteristic of a patient to select them for a clinical trial 
— this may be prior response to a certain drug, or it also may be a prediction that they are 
more likely to decline (FDA, 2013). In the AD field, some clinical trials now select patients 
based on having a PiB-positive PET scan (Ikonomovic et al., 2008) – as evidence of 
incipient AD pathology – and the APOE4 risk genotype, as carriers are more likely to 
develop AD. This selective enrolment allows faster, less costly, and more well powered 
clinical trials, with demonstrable reductions in the number of patients needed to show 
treatment effects (Hua et al., submitted for publication).
ENIGMA's disease working groups are likely to broaden the set of known factors that help 
predict recovery or decline. In ENIGMA-HIV, for example, a key goal is to understand 
predictors of resilience — factors that might forecast healthy brain development after the use 
of antiretroviral treatment (Fouche et al., 2015). Crucially, it is important to know if a 
predictor of decline is specific to one cohort or likely to generalize to others, or if it is 
applicable in a limited set of situations. Understanding how APOE4 and other major risk 
genes shift the lifetime trajectory of brain measures will also help determine how much they 
will help when used for clinical trial stratification. This is a goal of the ENIGMA-Lifespan 
group (Dima et al., 2015). Clearly, any predictors of suicidal behavior would be very 
important in the management and follow-up of patients with psychiatric disorders (Mathews 
et al., 2013), and a secondary project on suicidality was started within the ENIGMA-
Depression working group (Rentería et al., submitted for publication). Similarly, factors that 
predict whether ADHD in a child will persist into adulthood, will have clinical utility 
(Hoogman et al., 2015). Ultimately, the stratification or clustering of ENIGMA cohort data 
into subtypes, based on imaging, clinical or behavioral data, may point to distinctions that 
help us understand the heterogeneity of these disorders. This heterogeneity, without models 
to disentangle it, makes individual patient predictions harder to make.
Normative Data Across the Human Lifespan
One effort where ENIGMA may contribute to individual prediction and evaluation – albeit 
with some caveats – is the ENIGMA-Lifespan project (Dima et al., 2015). In this work, 
ENIGMA cohorts are invited to contribute volumetric measures from normal individuals in 
their samples, which span the age range from 2 to 92 years of age. Although some cohort 
studies focus on children or the elderly, many scan people across the lifespan, allowing the 
computation of age-trajectories for several key brain measures; the results show a 
remarkable difference in the maturational trajectory of different structures, supporting many 
earlier neurodevelopmental reports on the sequence of brain development (Gogtay et al., 
2004; Sowell et al., 2004). To cope with the non-uniform sampling density of the cohorts, 
these overall trajectories must be interpreted cautiously; clearly some parts of the lifespan 
are better sampled than others, and unmodeled effects of scan site, demographics, and even 
cultural or environmental differences may drive some of the effects. Clearly, disentangling 
the driving factors is statistically complex, but the potential is there, to derive normative 
measures and models of our path through life, in cohort studies as diverse as ENIGMA. The 
life span analyses (and normative curves) are also highly relevant for neurodevelopmental 
disorders such as OCD, ADHD, autism, etc. — for early detection, and secondary 
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prevention in at-risk populations. Eventually, there may even be efforts to train individuals in 
specific domains, to stimulate the maturation of specific brain areas that appear to be deviant 
from the norm curves.
Such normative data have possible applications for individual assessment, if used 
judiciously. In pediatrics, growth charts for height and weight offer metrics of where a child 
stands relative to others of the same age, as a Z-score for example. Similar metrics for brain 
structure, among others, may help in studies of neurodevelopment where interventions and 
treatments are used to promote healthy maturation, or recovery, as in the case of brain 
trauma, for example. Similarly, better trajectories to chart loss of brain volume with 
advancing age help in routine diagnosis of the individual with possible cognitive problems, 
by indicating first if their brain is within normal limits for age, and secondly the precise 
centile on which it lies (Farrell et al., 2009; Dickie et al., 2013, in press) – much more data is 
needed to populate these graphs, but (much like child growth charts) they have the potential 
to be highly valuable in routine clinical practice as well as research. Original scan data are 
being collected to expand these templates (e.g., www.brainsimagebank.ac.uk).
Norming of brain measures also has commercial applications (Ochs et al., 2015). ENIGMA 
relies heavily on developments in software for imaging and genotype acquisition, quality 
control, and analysis, that make standardized assessment possible. In some regions of the 
world, such as Thailand and Cambodia, ENIGMA has contributors who are interested in 
whether it makes sense to use brain development norms from Western cohorts, or build their 
own (Jahanshad et al., 2015a,b,c; Fouche et al., 2015). By comparing developmental 
trajectories across very diverse multi-cohort data, better answers to these and other practical 
questions are within reach.
Machine Learning, Big Data, and Individual Prediction
With the advent of very large neuroimaging datasets, we can fit predictive models to the data 
and test them for their robustness. Our models of how diseases and genes affect the brain are 
constantly being tested and improved, especially in situations where statistical effects have 
previously been too small to discover, or have been confounded by factors that cannot be 
adjusted for. In GWAS for example, there are known genetic differences in allele frequencies 
across populations, and if these are not accurately modeled based on much larger datasets, 
and adjusted for using multidimensional scaling, they will confound the analysis and lead to 
spurious results - many more SNPs will show “effects” on the brain, ultimately turning out 
to be false positives. Years of “false alarms” (Farrell et al., 2015) led the genomics 
community to adopt strict standards for reporting effects, including a standard genome-wide 
significance threshold (described above). In addition, independent replication of effects is 
required. In imaging, a somewhat more flexible approach has been used, with approaches 
from FDR to random field theory and permutation all co-existing in the literature; the use of 
candidate brain regions or prior hypotheses in functional imaging studies is encouraged, but 
the use of candidate regions in genomics is sometimes hotly debated as leading to many 
false positive effects (Collins et al., 2012; Farrell et al., 2015; ENIGMA-DTI Working 
Group, 2014). Munafò and Kempton (2014) argued that the growing flexibility in analyses 
used in neuroimaging is increasing the reporting of false positive results, and meta-analyses 
Thompson et al. Page 18
Neuroimage. Author manuscript; available in PMC 2018 January 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
may offer better estimates of the validity of claims regarding brain differences in major 
depression and bipolar illness, fields for which they meta-analyzed the neuroimaging 
literature.
Given the sample sizes attained, ENIGMA offers a framework not only for unrestricted 
searches, but also to test more focused hypotheses and provide internal replication using, for 
example, cross-validation methods. So far, the Working Groups have over 30 “secondary 
proposals”: many study clinical measures, disease subtypes, and patterns of behavior such as 
suicidality or negative symptoms, or other differences that might contribute to the 
heterogeneity of brain disease and outcomes. One such project, in the ENIGMA-Major 
Depression group, assesses the effects of childhood trauma on depression-related brain 
measures, a factor that may be modeled effectively by comparisons with data from the 
ENIGMA-PTSD group, where childhood trauma is also a major predictive factor. 
Partnerships between ENIGMA groups may resolve some sources of brain differences that 
are difficult to disentangle. In HIV+ people who abuse stimulant drugs, for example, white 
matter inflammation is commonly reported, while patterns of accelerated atrophy are often 
seen in HIV+ people who do not use intravenous drugs, especially in those carrying the 
APOE4 genotype. These and other predictors can be assessed in partnerships between the 
ENIGMA-Addictions and ENIGMA-HIV groups, by determining a common core of 
predictor variables that can be harmonized.
More refined models are also needed: we now know that the profile and extent of brain 
differences in disease may depend critically on a patient's age, duration of illness and course 
of treatment, as well as adherence to the treatment, polypharmacy and other unmeasured 
factors. Differences in ancestral background, as determined based on genotype, are strongly 
related to systematic differences in brain shape (Bakken et al., 2011; Fan et al., 2015). Any 
realistic understanding of the brain imaging measures must take all these into account, as 
well as acknowledge the existence of causal factors perhaps not yet known or even 
imagined. The quest to identify individual predictors is therefore more likely to succeed in 
finding factors that affect aggregate risk and outcome in groups of individuals, rather than 
offer firm predictions regarding an individual.
A more immediately achievable goal, for ENIGMA, is to rank brain measures in terms of 
how well they do predict individual decline, or diagnosis. Predictors of imminent brain 
decline are already used to boost the power for clinical trials in Alzheimer's disease, by over-
enrolling, or separately analyzing patients whose brain measures, or clinical and genomic 
measures, suggest that they will decline faster. In ENIGMA, the ENIGMA-Plasticity group 
is evaluating the genetic influences on measures of brain change, in a meta-analytic setting 
(Brouwer et al., 2015). If reproducible drivers of brain decline could be found by screening 
brain data worldwide, they would help in planning enrichment approaches for drug trials. 
Several major initiatives have this goal (e.g., ADNI; Jack et al., 2015). Currently, the only 
genetic marker used for enrichment is APOE, but this may change as more information 
accumulates (see Lupton et al., submitted for publication). The complex pattern of 
association between brain measures and SNPs across the APOE gene (Hibar and the 
CHARGE and ENIGMA2 Consortia, submitted for publication; Hibar et al., 2015a,b, in 
press) suggests that future polygenic predictors based on machine learning may better 
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predict clinical decline, and decline in brain measures, than the standard APOE genetic test, 
which is based on just 2 SNPs.
Machine Learning
Innovations in machine learning make it possible to build robust predictive models from 
millions of predictors, often using dimension reduction techniques to home in on more 
efficient sets of variables that explain the most variance in the data; this vast field, including 
sparse learning and compressive sensing, is especially valuable in imaging genomics, with 
millions of predictors in both the images and the genome. Several machine learning 
developments have been applied to connect genomic and imaging measures, using methods 
such as parallel ICA (Gupta et al., 2015; Calhoun et al., 2015), elastic net (Wan et al., 2011), 
sparse reduced rank regression (sRRR; Vounou et al., 2010), among others. ENIGMA is 
beginning to test some of these models, specifically in the disease working groups, for case-
control differentiation and differential diagnosis. Past efforts to combine imaging and 
genomic data for outcome prediction suggest that imaging measures may be much more 
predictive of future clinical decline than genomic measures, but both are complementary 
(Peters and the Alzheimer's Disease DREAM Challenge, submitted for publication). 
Predictive models should improve as they draw on more data, and the larger ENIGMA 
GWAS studies are now discovering more genetic markers that can be used in predictive 
models for brain measures (Hibar and the CHARGE and ENIGMA2 Consortia, submitted 
for publication; Hibar et al., 2015a,b, in press; Adams and the CHARGE and ENIGMA2 
Consortia, submitted for publication). However, compelling as these approaches are and not 
wishing to dampen the enthusiasm for these very promising techniques, the image 
measurements being predicted generally require a human check and correction if necessary, 
particularly in datasets with complex imaging features such as occur in older patients with 
stroke – machine learning analysis algorithms still cannot reliably separate the 
hyperintensity due to a small cortical infarct from that due to a white matter hyperintensity 
or artifact, reliably. Also, the variants driving the heritability of disease risk are only just 
beginning to be discovered for many of the major brain diseases studied within and outside 
of ENIGMA. Unsupervised learning is also relevant for understanding the heterogeneity of 
diseases, which has made it harder to discover their causes and mechanisms. Brodersen et al. 
(2013) argued that one could use unsupervised learning on imaging, clinical and genetic data 
to see whether subtypes (or clusters) can be identified within a disease, and whether these 
data cluster together in agreement (or disagreement) with current diagnostic classifications.
In conclusion, we have reviewed current work by the ENIGMA Consortium. ENIGMA 
began in 2009, and is now a distributed effort, with over 30 working groups (see Table 1), 
coordinated from many centers worldwide. As we noted, ENIGMA's main goals have been 
to detect effects of disease and genetic variants on the brain, to see how consistent these 
effects are worldwide, and to study what modulates these effects. On the genetic side, it may 
soon be possible for polygenic scoring to produce predictors that are routinely used in brain 
imaging studies, explaining some of the observed variance. This may make other effects 
easier to detect. On the disease side, we are beginning to identify and confirm distinctive 
patterns of brain differences in each of a range of brain diseases, along with a better 
understanding of which patterns are specific to given disorders, which patterns tend to 
Thompson et al. Page 20
Neuroimage. Author manuscript; available in PMC 2018 January 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
generalize, and what factors account for the heterogeneity across cohorts. This will help us 
understand the situations where predictive models can be used, for diagnostic classification, 
outcome prediction, and norming of individual data against appropriate reference 
populations.
We end with a note in praise of small studies. Like any consortium, ENIGMA would be 
impossible without the cohort studies and all the individuals who contribute; most of the 
data analyzed in ENIGMA came from cohorts with relatively modest sample sizes. 
Inevitably, many hypotheses are not addressable on a large scale, and some questions - 
especially causal questions - involve targeted interventions or phenotypic assessments with a 
depth or sophistication not likely to be attained at every site. As Aristotle said, “Nobody has 
the ability to work everything out, but everyone has something useful to say; working 
together, the whole vast world of science is within our reach.” (ἐκ πάντων δὲ 
συναθροιζομένων γίγνεσθαί τι μέγεθος; Aristotle, Metaphysics α, c. 350 BCE). 
This is the ENIGMA motto: http://enigma.ini.usc.edu/about-2/.
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Fig. 1. 
Recent genome-wide association studies (GWAS) of brain disorders and brain structure. 
Part A shows the Manhattan plot from a 2014 Nature meta-analysis conducted by the 
Psychiatric Genomics Consortium. The genetic variants are presented on the x-axis, and the 
height of the dots shows the strength of association between each genetic variant and 
schizophrenia. A negative log p-value scale is used: higher points denote stronger 
associations. The group identified 108 schizophrenia-associated genetic loci in a sample of 
34,241 cases and 45,604 controls (red line = genome-wide significance level, conventionally 
set at p = 5×10–8; green SNPs = polymorphisms in linkage disequilibrium with index SNPs 
(diamonds), which indicate independent genome-wide significant signals). Part B 26 loci 
significantly associated with risk of Parkinson's Disease (Nalls et al., 2015), in 13,708 cases 
and 95,282 controls (red SNPs = genome-wide significant signals). Part C 19 loci 
significantly associated with risk of AD, in a sample of 17,008 cases and 37,154 controls 
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(Lambert et al., Nature Genetics, 2013; genes identified by previous GWAS are shown in 
black; newly associated genes in red; red diamonds indicate SNPs with the smallest overall 
p-values in the analysis). Part D shows genome-wide associations for eight subcortical 
structures, conducted by the ENIGMA consortium in 30,717 individuals from 50 cohorts 
worldwide (Hibar et al., Nature, 2015). This study identified five novel genetic variants 
associated with differences in the volumes of the putamen and caudate nucleus and stronger 
evidence for three previously established influences on hippocampal volume (see Stein et 
al., Nature Genetics, 2012) and intracranial volume (see Ikram et al., Nature Genetics, 
2012). Each Manhattan plot in Part D is color-coded to match its corresponding subcortical 
structure, shown in the middle row. The gray dotted line represents genome-wide 
significance at the standard p = 5×10–8; the red dotted line shows a multiple-comparison 
corrected threshold of p = 7.1 × 10–9. [Images are reproduced here with permission from 
MacMillan Publishers Ltd (Nature Genetics, 2012 & 2013; Nature, 2014 & 2015) and with 
permission from the corresponding authors.]
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Fig. 2. ENIGMA Map
The ENIGMA consortium now consists of over 30 Working Groups made up of 500 
scientists from over 200 institutions and 35 countries; several of these Working Groups have 
several ongoing secondary projects, led by different investigators. Here we show 12 of the 
working groups, focusing on specific diseases and methodologies, including ADHD, autism, 
addiction, bipolar disorder, diffusion tensor imaging, epilepsy, HIV, major depressive 
disorder, OCD, PTSD and schizophrenia. Centers where individuals are scanned and 
genotyped are denoted with color-coded pins (legend, bottom left).
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Fig. 3. ENIGMA Roadmap
The current organization of ENIGMA's Working Groups is shown here. Several groups 
relate brain measures to variation in the genome, and specialized groups are dedicated to 
helping members run analyses of genome-wide SNP data, copy number variants, and 
epigenetic markers on the genome. In parallel, there are psychiatric and neurology working 
groups dedicated to the study of worldwide data from a range of diseases. As shown here in 
detail for the schizophrenia working group, there are secondary projects, to relate brain 
variation to specific symptoms or clinical measures. In parallel, support groups coordinate 
large scale efforts to harmonize DTI (diffusion tensor imaging) and related brain data 
(Jahanshad et al., 2014). Partnerships between the DTI and Genomics groups are leading to 
genome-wide screens of DTI measures in over 13,000 people; cross-disorder partnerships 
study brain features that may relate to diagnostic boundaries, or common co-morbidities, 
allowing factors driving brain variations to be disentangled.
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Fig. 4. 
ENIGMA's studies of brain differences in disease revealed consistent patterns of subcortical 
volume differences across multiple cohorts with schizophrenia and major depression (data 
reproduced, with permission, from van Erp et al., 2015; Schmaal et al., 2015, Molecular 
Psychiatry). Here we show the effect sizes (Cohen's d), for the mean volume difference 
between patients and matched controls, for a range of brain structures measured from MRI. 
After meta-analysis of all cohorts, in schizophrenia, a range of subcortical structures showed 
volumetric differences, including hypertrophy, which may be due in part to antipsychotic 
treatment. In major depression, the hippocampus is smaller in the depressed groups. Such 
data, for these and other brain measures, is now being compiled and analyzed across 12 
disorders in ENIGMA (see Table 1 for a summary), and may be useful for classification, so 
long as relevant confounds, site effects, and co-morbidities are appropriately modeled and 
understood.
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Fig. 5. Meta-Analyzing Statistical Brain Maps
As in other fields of brain mapping, voxel-based statistical analyses can map statistical 
associations between predictors and brain signals. To meta-analyze maps of statistical 
associations across sites, Jahanshad et al. (2015a,b,c) proposed a method whereby each site 
aligns data to their own brain template (mean deformation template, or MDT). Statistics 
from each site are meta-analyzed at each voxel, after a second round of registration to an 
overall mean template (computed here from 4 cohorts representing different parts of the 
lifespan). Analyses proceed in parallel, using computational resources across all sites; 
analyses are updated when a new site joins. This approach applies equally to voxel-based 
maps of function, and the ENIGMA-Shape working group has modified it to work with 
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surface-based coordinates (Gutman et al., 2015a,b,c). If structural labels are used to drive the 
multi-channel registration (top panels), in conjunction with an approach such as tensor-based 
morphometry, the resulting local volumetric measures should closely mirror volumetric 
findings for specific regions of interest. As such, some results of brain-wide genome-wide 
searches can be checked by consulting genome-wide association results for specific regions 
of interest (Hibar et al., 2015a,b; Adams and the CHARGE and ENIGMA2 Consortia, 
submitted for publication).
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Table 1
ENIGMA working groups, showing the number of independent participating samples, and the total sample 
size analyzed to date. A range of recruitment methods are represented. Some ENIGMA working groups, such 
as ENIGMA-Lifespan, ask questions that can be answered in healthy cohorts – often participants are controls 
from psychiatric studies, or population based samples, in which people with a current psychiatric diagnosis 
may be excluded altogether. Members of ENIGMA disease working groups have contributed their controls to 
several ongoing studies, leading to normative samples of unprecedented size (over 10,000 in the Lifespan and 
15,000 in the Lateralization groups). Some working groups study clinic-based samples of cases and controls, 
and others study samples enriched for certain risk factors: over half of the people enrolled in ADNI, for 
example, have mild cognitive impairment, which puts them at heightened risk for developing Alzheimer's 
disease. In ENIGMA-Lateralization, one participating cohort (BIL&GIN) enrolls left-handers at a higher 
frequency than found in the general population, to boost power to understand handedness effects. Study 
designs, enrolment and sampling approaches vary widely across cohorts taking part in ENIGMA, so several 
ENIGMA studies assess how much difference it makes to restrict or broaden analyses in certain ways, such as 
pooling or separating certain categories of patients. Genetic analyses, for example, are typically run twice, first 
including patients and then excluding them. Disease group analyses may assess brain differences in different 
patient subgroups – chronically ill versus first-episode patients, at-risk siblings versus the general population, 
or people with different symptom profiles, or with distinct etiologies (e.g., negative symptoms, whose origin 
may differ in schizophrenia, addiction, or PTSD).
ENIGMA working groups Number of cohorts Total N (patient N) Age range (in 
years)
Relevant publication(s)
ENIGMA2 GWAS (Subcortical) 50 30,717 (3,277 patients) 8-97 Hibar +287 authors, 
Nature, Jan. 2015
ENIGMA3 GWAS 50 + 32,000+ (4,000 patients) 8-97 In progress
ENIGMA DTI GWAS 35 13,500 (3,000 patients) neonates-90 (Kochunov et al., 2014, 
2015 NIMG; Jahanshad et 
al., 2013a,b NIMG)
ENIGMA EEG 4 10,155 (1,000 patients) 5-74 In preparation
ENIGMA-CNV 24 13,057 (1,800 patients) 13-90 In preparation
ENIGMA-Epigenetics 14 9,000 Across the lifespan In preparation
ENIGMA-Schizophrenia 26 7,308 (2,928 patients) average dataset age 
ranges from 21 to 
44
van Erp et al., 2015, Mol 
Psych.
ENIGMA-MDD (Major depression) 20 10,105 (2,148 patients) 12-100 Schmaal et al., 2015, Mol 
Psych.
ENIGMA-BPD (Bipolar disorder) 20 4,304 (1,710 patients) 16-81 Hibar et al., in press, Mol 
Psych.
ENIGMA-ADHD 23 3,242 (1,713 patients) 4-63 Hoogman et al., OHBM, 
2015, under review Am J 
Psychiatry
ENIGMA-OCD 35 3,722 (1,935 patients) 6-65 In preparation
ENIGMA-Epilepsy 23 6,569 (3,800 patients) 18-55 In preparation
ENIGMA-PTSD 15 4,555 (1,050 patients) 8-67 In preparation
ENIGMA-Parkinson's 4 950 (626 Patients/SWEDD) 30-85 In preparation
ENIGMA-22q 22 1,020 (554 patients) 6-50 in preparation; Sun et al., 
SFN 2015 (abstract); 
Schneider et al., AJP, 
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ENIGMA working groups Number of cohorts Total N (patient N) Age range (in 
years)
Relevant publication(s)
2014; Vorstman et al., 
JAMA Psych, 2015
ENIGMA-ASD (Autism Spectrum 
Disorders)
20 1,960 (1,074 patients) 3-46 In preparation
ENIGMA-HIV 10 650 (all patients) 6-85 Fouche et al., OHBM, 
2015; Nir et al., CNS, 
2015
ENIGMA-Addictions 21 12,458 (3,820 patients) 7-68 Mackey et al., PBR, 2015
ENIGMA-GCTA 5 4,000+ 14-97 In preparation
Secondary Projects Number of cohorts Total N Age 
range 
(in 
years)
Relevant publication(s)
ENIGMA-Lifespan 91 10,672 (healthy only) 2-92 Dima et al., 2015
Psychiatric cross-disorders 87 21,199 for 4 of the 
disorders (7,294 patients)
Schizophrenia: 4,568 
(2,028 patients)
Bipolar Disorder: 4,358 
(1,745 patients)
Major Depression: 9,031 
(1,808 patients)
ADHD: 3,242 (1,713 
patients)
4-100 -
ENIGMA-Lateralization 48 15,531 (0 patients) 8-90 Guadalupe et al., OHBM, 
2015, submitted for 
publication
ENIGMA-Plasticity 10 2,513 (2,153 healthy 
controls; 290 
schizophrenia patients; 70 
bipolar disorder patients)
9-73 Brouwer et al., OHBM, 
2015
ENIGMA-vGWAS meta-analysis 7 6,000 21-90 Jahanshad et al., OHBM, 
2015, MICCAI 2015
ENIGMA-Schizophrenia-DTI 16 4,180 (1,927 patients) 18-60 Kelly et al., OHBM, 2015
ENIGMA-Schizophrenia-Relatives 8 4,079 (1,769 controls, 906 
schizophrenia patients, 
1,404 relatives)
8-58 In preparation
ENIGMA-Schizophrenia-shape 2 462 (159 patients) 16-75 Gutman et al., OHBM, 
2015; Gutman et al., ISBI, 
2015
ENIGMA-ILAE polygenic risk collaboration 12 34,992 (8,835 patients) 18-70 Whelan et al., 2015
ENIGMA-MDD (Major depression) DTI 15 2,100 (800 patients) 12-100 In preparation
ENIGMA-PGC Schizophrenia Collaboration PGC Schizophrenia 
and ENIGMA2 
summary statistics
PGC-Schizophrenia 
GWAS was based on 
36,989 patients and 
113,075 controls
8-97 Franke et al., in press; 
Stein et al., 2015
ENIGMA-Connectome-Methods harmonization 3 127 (healthy only) 21-85 de Reus et al., 2015
Abbreviations: SWEDD = scans without evidence of dopaminergic deficit.
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